TCMG and Mengyang Pharmaceutical said on July 21 that they have completed a cross-border licensing deal for Shengbai Oral Liquid, with TCMG getting exclusive U.S. marketing rights for 20 years and Mengyang retaining ownership, intellectual property, development and manufacturing rights. The deal is worth up to $3 million, including a one-time nonrefundable upfront payment of $225,000 and later commercial milestone payments, according to Jiemian News.
TCMG founder Gao Yuan said the payments were tied to Mengyang Pharmaceutical's long-term exclusive supply arrangement. Mengyang chairman Zhang Min said Shengbai has completed the relevant U.S. filings for dietary supplements, and the partners are preparing for a U.S. launch by building clinical evidence, strengthening regulatory compliance, ensuring batch consistency and developing the market.
Shengbai Oral Liquid is Mengyang Pharmaceutical's main product and is used in China as a supportive treatment for low white blood cell counts caused by radiotherapy and chemotherapy. The company is the sole supplier in China, according to pharmaceutical database pharnexcloud.com, and its hospital-channel sales reached 276 million yuan in 2025. Gao said the U.S. route was chosen as a dietary supplement rather than a drug, which should lower entry barriers but leaves more risk to commercialization.
TCMG, Mengyang Pharmaceutical Complete $3 Million U.S. Licensing Deal for Shengbai Oral Liquid
2026-07-28 03:52:57
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
